Continuing Education Activity

Isoniazid (INH) is an antibiotic indicated in the first-line treatment of active Mycobacterium tuberculosis (TB) infection. INH has been a significant drug in TB treatment regimens for decades. INH functions as a prodrug activated by the catalase-peroxidase KatG, generating various radicals and adducts that inhibit the production of mycolic acids, the essential components of the mycobacterium's cell wall. This mechanism of action makes INH a potent bactericidal agent. Moreover, INH exhibits synergistic effects with other species generated by KatG and other medications utilized in TB treatment.

Mutations in the katG, inhA, kasA, and ahpC genes can lead to resistance against INH therapy. Resistance of M tuberculosis can occur more rapidly with INH monotherapy. This activity reviews the indications, mechanism of action, and contraindications of INH as a valuable agent in treating both active and latent TB infections. This activity also highlights the drug's adverse event profile, regimens and dosing, and other key factors pertinent to the interprofessional healthcare team when using INH for TB treatment.

Objectives:

• Identify patients with active or latent tuberculosis who can benefit from isoniazid (INH) treatment based on clinical guidelines and risk factors.
• Screen patients for risk factors predisposing them to adverse reactions or interactions with isoniazid (INH), considering comorbidities and concomitant medications.
• Apply knowledge of isoniazid's (INH's) mechanism of action and pharmacokinetics to optimize dosing and minimize the risk of resistance.
• Collaborate with other healthcare professionals to coordinate comprehensive tuberculosis management, including monitoring for adverse effects, drug interactions, and treatment outcomes.

Indications

Isoniazid (INH) is an antibiotic indicated in the first-line treatment of active Mycobacterium tuberculosis infection.

FDA-Approved Indications

The US Food and Drug Administration (FDA) approved INH for the following indications:

• Active tuberculosis (TB) infection can present as fever, chills, night sweats, cough, hemoptysis, and weight loss. Four CDC-recommended multiple-drug regimens involve INH for drug-susceptible strains. The regimens consist of an initial phase of 2 months followed by a continuation phase of either 4 or 7 months.[1]

• Latent TB infection, although rifampin-based regimens have recently replaced INH as the primary recommendation. Rifampin-based regimens have demonstrated similar efficacy with a shorter treatment course and better completion rates.[2]

• Patients with HIV infection with purified protein derivative (PPD) tuberculin skin test ≥5 mm induration and in patients with risk factors for HIV infection with high suspicion of HIV infection.[3]

• Individuals with close contact with patients having TB and PPD ≥5 mm.

• Preventive therapy is indicated with fibrotic pulmonary lesions with recovered TB or in patients having pulmonary silicosis.[4]

• Intravenous (IV) drug users with PPD ≥10 mm.[5]

Off-Label Use

According to the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), INH is indicated for treating nontuberculous mycobacterial pulmonary disease.[6]

Mechanism of Action

Isoniazid has been a significant drug in TB treatment regimens since 1952. INH is a prodrug activated by the catalase-peroxidase KatG, creating a variety of radicals and adducts that inhibit the mycobacterium's production of the mycolic acids that make up its cell wall. This activity lends INH the ability to be a potent bactericidal agent. The drug also appears synergistic with other species produced by KatG and other medications used to treat TB.[7] However, mutations in the katG, inhA, kasA, and ahpC genes may cause resistance to INH therapy. M tuberculosis resistance develops more rapidly with INH monotherapy.[8][9]

Pharmacokinetics

Absorption: Rapid and complete absorption occurs after oral or intramuscular (IM) administration. The time of peak plasma concentration is 1 to 2 hours. INH is absorbed by the small intestine and is transported by the portal system to the liver.

Distribution: INH is rapidly distributed into all body tissue compartments, including cerebrospinal fluid. Plasma protein binding is 10% to 15%. 

Metabolism: INH is inactivated via acetylation by N-acetyltransferase 2 (NAT2) in the liver and intestines. Following the acetylation of INH, CYP2E1 oxidizes acetyl hydrazine into hepatotoxic metabolites. Rapid metabolizers can oxidize faster, which may increase the synthesis of hepatotoxins. Glutathione S-transferase (GST) protects against hepatotoxins. Combining GST with toxic metabolites forms relatively non-toxic and water-soluble metabolites that can be excreted easily.

Elimination: Most of the unchanged drug (75% to 95%) and its metabolites are excreted in the urine, while small amounts are excreted in feces and saliva.[10]

Administration

Available Dosage Forms and Strengths

Available INH formulations are tablets (100 and 300 mg), syrup (50 mg/5 mL), or IV or IM injection (100 mg/mL). In adults, 5 mg/kg up to 300 mg daily as a single dose daily, or 15 mg/kg up to 900 mg/d in 2 to 3 divided doses per week is recommended, depending on the treatment regimen chosen. Clinicians should advise the patient not to take INH with food as the bioavailability is decreased when administered with food. 

Active TB: According to the joint guidelines by the American Thoracic Society, Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America, the preferred regimen for active TB infections with drug-susceptible strains consists of 8 weeks of intensive phase treatment with INH, rifampin, pyrazinamide, and ethambutol (the RIPE regimens), followed by 18 weeks continuation phase treatment with INH and rifampin. Pyridoxine (vitamin B6), 25 to 50 mg/d, is administered with INH. The recommended dose of pyridoxine for patients with peripheral neuropathy is increased to 100 mg/d.[11]

Latent TB infection: Untreated latent TB infection has approximately a 5% to 10% risk of progression to TB during the patient's lifetime. According to the guidelines by the CDC, for the treatment of latent TB infection, the preferred regimen is 3 months of INH plus rifapentine, given weekly. An alternative regimen is 9 months of INH, given daily.[12]

Dosing regimens for adults and children aged 12 and older: INH and rifapentine (RPT) – given weekly for 3 months (12 doses).

• INH 15 mg/kg rounded up to the nearest 50 or 100 mg; 900 mg maximum

• RPT dosed 300 to 900 mg based on patient body weight

INH and rifampin (RIF) – dosed daily for 3 months (90 doses)

• INH 5 mg/kg; 300 mg maximum

• RIF 10 mg/kg; 600 mg maximum

INH monotherapy – dosed for 6 or 9 months

• 6-month regimens:

  • INH 5 mg/ kg daily; maximum dose 300 mg (180 doses)
  • INH 15 mg/kg twice weekly; maximum dose 900 mg (52 doses)

• 9-month regimens:

  • INH 5 mg/kg daily; maximum dose 300 mg (270 doses)
  • INH 15 mg/kg twice weekly; maximum dose 900 mg (76 doses)

Nontuberculous mycobacterial pulmonary disease: According to a joint guideline by ATS, IDSA, European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and European Respiratory Society (ERS), patients with M kansasii infection (rifampicin-susceptible M kansasii) should be treated with daily administration of rifampicin, INH, and ethambutol. This regimen is associated with increased treatment success and lower relapse rates. Treatment should be continued for at least 12 months. The recommended dose of INH is 5 mg/kg up to 300 mg daily.[6]

Specific Patient Populations

Hepatic impairment: The manufacturer's labeling provides no dose adjustment guidance for patients with hepatic impairment. However, INH is metabolized in the liver, so the drug should be used cautiously in these patients. Dose adjustment may be required for acute or chronic liver disease patients to avoid adverse effects.[13] 

Renal impairment: No dose adjustment is needed for patients with renal impairment. The recommendations are to administer a full dose of INH in patients with impaired renal function despite prolonging the drug's half-life.[13] No supplement is required for patients on peritoneal or hemodialysis.

Pregnancy considerations: INH is considered an FDA pregnancy category C medicine. INH may cross the placental barrier. Although INH may not cause teratogenic effects, careful monitoring of pregnant patients is recommended. Using INH therapy to treat active TB during pregnancy is recommended as the benefit outweighs the potential risk to the fetus. Pyridoxine supplementation is a recommended intervention for these patients.

According to the CDC, the risk of untreated active TB disease in the pregnant woman and fetus is greater than the risks of treatment. Congenital TB can cause bronchopneumonia and hepatosplenomegaly in neonates, with a high mortality rate. For drug-susceptible TB, 9 months of treatment with INH, rifampin, and ethambutol should be given, considering the risk-benefit evaluation.[14]

Breastfeeding considerations: The manufacturer recommends not discouraging breastfeeding as the small amount of INH in breast milk does not produce toxicity in the infant. Pyridoxine supplementation is recommended for these patients.[15]

Pediatric patients: According to the CDC and the National Tuberculosis Controllers Association, the preferred regimen for latent TB infection is 3 months of weekly INH plus rifapentine in children aged older than 2 years by directly observed therapy. The INH dose for children 2 to 11 years is 25 mg/kg/dose; for ages 12 and older, it is 15 mg/kg/dose. An alternative regimen is 9 months of daily INH (10 to 20 mg/kg).[12] For active TB infection, INH is always used with other antitubercular drugs; INH is 10 to 15 mg/kg daily or 20 to 30 mg/kg given twice weekly by directly observed therapy.[11]

Older patients: No specific dose adjustment guidance is recommended in the manufacturer label for older patients. Clinicians should exercise caution as the mortality from TB is increased in older patients.[16]

Adverse Effects

Various adverse effects have been reported with INH use; most are transient and low-grade. Patients commonly experience gastrointestinal effects; some also report rash and pruritus. Peripheral neuropathy is also a commonly associated adverse event of INH therapy, although its incidence is less than 0.2%. The risk may increase in patients with diabetes, HIV, nutritional deficiency, renal failure, alcoholism, and in women who are pregnant or breastfeeding. The mechanism of INH-induced peripheral neuropathy appears to involve interference of INH metabolites with vitamin B6 (pyridoxine) metabolism, resulting in decreased amounts of biologically active B6. Thus, the treatment and prevention of peripheral neuropathy caused by INH is pyridoxine supplementation during treatment.[1][17]

INH is also a CYP450 inhibitor (2C19: moderate, 3A4: weak), potentially resulting in elevated serum concentrations of concurrent drugs such as phenytoin, carbamazepine, diazepam, and primidone. Slow acetylation may be at a higher risk for these drug-drug interactions.[18]

Drug-induced lupus erythematosus (DILE) has been reported in up to 1% of patients taking INH. Half of the patients in these cases present with fever and pleuritis, and 30% with pericarditis. Some experts think that slow acetylation poses an increased risk for the development of INH-induced lupus.[19] Anti-histone antibodies are positive in most cases of drug-induced lupus.[20] Patients on chronic hemodialysis are at increased risk of developing severe encephalopathy.[21]

Drug-Drug Interactions

• INH is a CYP450 inhibitor, potentially resulting in elevated serum concentrations of drugs such as diazepam and primidone. Slow acetylators may be at a higher risk for these drug-drug interactions.[18]

• INH increases the plasma concentration of phenytoin. Therefore, to avoid phenytoin toxicity, phenytoin dose adjustment is advised.[22]

• Increased acetaminophen toxicity is reported with concurrent administration of INH. INH increases the metabolism of acetaminophen, resulting in a reduction of glutathione. INH is also a potent inducer of CYP2E1, forming toxic metabolites and subsequent hepatotoxicity.[23]

• INH inhibits the metabolism of carbamazepine, resulting in increased concentration and toxicity of carbamazepine. Therefore, the dose adjustment of carbamazepine is recommended.[16]

• Administration of INH with theophylline may cause increased plasma levels of theophylline. As theophylline has a narrow therapeutic index, therapeutic drug monitoring is recommended.[24]

• Intravesical bacillus Calmette–Guérin (BCG) vaccination is contraindicated with concurrent use of INH.[25]

Contraindications

Warnings and Precautions

INH can be administered to patients with stable liver disease, although the risk for drug accumulation and drug-induced hepatitis may increase. These patients should receive more frequent monitoring.[1] INH is contraindicated for patients with severe hypersensitivity reactions to INH or other formulation components.[26]

Box Warning

Drug-induced liver injury (DILI) has been well documented with INH. INH-associated hepatotoxicity usually occurs during the first 3 months of treatment. Enzyme levels typically return to normal despite the continuation of the drug, but progressive liver injury has been reported. Risk factors associated with increased hepatotoxicity are alcohol, preexisting chronic liver disease, IV drug abuse, and the postpartum period.[27]

Monitoring

In all adults preparing to begin INH treatment, the clinician should order baseline measurements of aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, alkaline phosphatase, serum creatinine, and platelet count. Regular monitoring of hepatic and renal function during treatment is unnecessary unless the patient has abnormal baseline levels or is at increased risk for hepatotoxicity such as alcohol misuse and hepatitis B or C infection. Serum transaminases should be measured again 2 to 4 weeks after treatment initiation for those patients.[1] In patients with pulmonary TB, monthly sputum specimens are necessary (until 2 consecutive negative cultures) to assess response to treatment. Patients with poor compliance history should be monitored with a urine test. Isoscreen test checks for INH metabolites in the urine.[28][29]

Toxicity

The liver metabolizes INH primarily by acetylation with N-acetyl transferase 2 (NAT2). Three metabolites have implications that correlate with the liver injury associated with the drug: acetyl hydrazine (AcHz), hydrazine (Hz), and a metabolite from the bioactivation of INH itself. Considerable variation is apparent in the acetylation rate and elimination half-life from individual to individual, which is not accounted for by dose and concentration. This appears to contribute to the risk of hepatotoxicity and the other adverse effects associated with the drug.[30]

Mild liver injury will occur in up to 20% of patients taking INH. Clinical manifestations of hepatotoxicity include fever, fatigue, nausea, and vomiting. However, most patients experiencing INH-induced liver injury are asymptomatic. Usually, the condition is detected only by measuring increased levels of ALT and AST, which may rise to as high as 5 times the normal limit. In “adaptation,” the hepatic markers will return to normal in most patients with continued drug administration. About 1% of patients will experience severe liver injury; INH therapy should cease immediately. Reintroducing INH in these cases is contraindicated as it can cause rapid symptom onset, and fatal hepatitis during INH treatment is associated with continued use after symptoms of hepatitis are present.[31] 

INH-induced severe liver injury is generally associated with older patients and can be further exacerbated by concurrent treatment with rifampin, which induces CYP metabolism. Incidence is also higher in slow acetylators, which correlates with higher serum levels of INH and the AcHz metabolite. Additional risk factors include preexisting liver disease, a history of heavy alcohol use, and patients in the postpartum period. More recently identified risk factors include polymorphisms in glutathione S-transferase, CYP2E1, TNF-α, and others.[30] Most patients recover entirely from INH hepatotoxicity following drug discontinuation, although complete regression takes weeks.[32]

INH doses above 30 mg/kg typically cause seizures, and doses exceeding 80 mg/kg can cause death. The most commonly reported adverse reactions to INH include seizures, coma, hyperthermia, and oliguria. Additionally, acute INH toxicity is associated with excess lactic acid produced during episodes of intense muscular rigidity.

Treating INH overdose requires establishing a secure airway and prompt treatment for hypotension and seizures. Pyridoxine helps to terminate seizures and should be administered in a 1:1 ratio of grams of INH ingested. Pyridoxine should be supplemented with IV benzodiazepines as pyridoxine and benzodiazepines display pharmacological synergism. INH has a low volume of distribution and low plasma protein binding; hemodialysis may be considered in refractory cases.[33]

Enhancing Healthcare Team Outcomes

Clinicians treating TB patients with INH must be aware of the patient's baseline liver function and the hepatotoxic risks associated with INH. Although estimates of fatal hepatitis associated with INH treatment are only 0.023%, these cases correlate with continued administration despite symptoms of hepatitis during treatment.[1]

TB has widespread effects and greatly burdens individual patients and communities. Appropriate treatment is crucial for limiting the spread of TB and preventing drug resistance. Therefore, a clinician treating TB prescribes the appropriate treatment regimen and ensures adequate treatment adherence and completion.[1] A growing concern is INH-resistant strains of TB, and it appears that these may serve as precursors to multidrug-resistant strains. Thus, clinicians should monitor patient progress to promptly detect patients not responding to INH treatment and who may harbor a resistant strain. INH-resistant strains require an altered regimen and increased efforts to prevent disease transmission.[34][35]

Public health departments typically provide TB treatment. They frequently collaborate as part of an interprofessional healthcare team with other entities such as private providers, community health centers, shelters, and others to ensure the completion of treatment. The interprofessional team should use a patient-centered approach to tailor a treatment plan specific to each patient's needs to provide the best opportunity for treatment completion. This approach often involves social workers, case managers, and medical professionals; optimal communication and coordination of services are essential. One way for the team to maximize adherence is through direct observation of therapy (DOT), in which healthcare professionals provide the medications directly to the patient and watch as they swallow them. This approach has become the preferred method of drug administration for TB treatment. DOT allows for early identification of nonadherence, adverse effects, or worsening of a patient's condition.[1] 

Nurses and pharmacists are also valuable members of this interprofessional approach by verifying doses, providing patient counsel, monitoring therapeutic progress, ensuring medication compliance, and monitoring adverse events. Nurses can use the DOT method to ensure medication compliance. Consultation from obstetricians is necessary for TB in pregnancy. Pediatricians play an essential role in the overall management of TB in children. Infectious disease consultation is crucial for multidrug-resistant TB and nontuberculous mycobacterial pulmonary disease. Interprofessional coordination and collaboration among physicians, advanced practice practitioners, specialists, pharmacists, nurses, and public health professionals can enhance patient outcomes when using INH therapy in treating TB infection.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA., American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62. [PubMed: 12588714]

2.

Huaman MA, Sterling TR. Treatment of Latent Tuberculosis Infection-An Update. Clin Chest Med. 2019 Dec;40(4):839-848. [PMC free article: PMC7043866] [PubMed: 31731988]

3.

Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, Anglaret X, Eholie S, Gabillard D, Boulle A, Maartens G, Wilkinson RJ, Ford N, Golub JE, Williams BG, Barnabas RV. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV. 2021 Jan;8(1):e8-e15. [PMC free article: PMC7875572] [PubMed: 33387480]

4.

Lanzafame M, Vento S. Mini-review: Silico-tuberculosis. J Clin Tuberc Other Mycobact Dis. 2021 May;23:100218. [PMC free article: PMC7868994] [PubMed: 33598569]

5.

Mamani M, Majzoobi MM, Torabian S, Mihan R, Alizadeh K. Latent and active tuberculosis: evaluation of injecting drug users. Iran Red Crescent Med J. 2013 Sep;15(9):775-9. [PMC free article: PMC3929809] [PubMed: 24616784]

6.

Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020 Aug 14;71(4):e1-e36. [PMC free article: PMC7768748] [PubMed: 32628747]

7.

Chakraborty S, Rhee KY. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm. Cold Spring Harb Perspect Med. 2015 Apr 15;5(8):a021147. [PMC free article: PMC4526730] [PubMed: 25877396]

8.

Ghodousi A, Tagliani E, Karunaratne E, Niemann S, Perera J, Köser CU, Cirillo DM. Isoniazid Resistance in Mycobacterium tuberculosis Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms. Antimicrob Agents Chemother. 2019 Jul;63(7) [PMC free article: PMC6591585] [PubMed: 31010866]

9.

Liu L, Jiang F, Chen L, Zhao B, Dong J, Sun L, Zhu Y, Liu B, Zhou Y, Yang J, Zhao Y, Jin Q, Zhang X. The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China. Emerg Microbes Infect. 2018 Nov 16;7(1):183. [PMC free article: PMC6240042] [PubMed: 30446638]

10.

Erwin ER, Addison AP, John SF, Olaleye OA, Rosell RC. Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. Tuberculosis (Edinb). 2019 May;116S:S66-S70. [PubMed: 31076322]

11.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 Oct 01;63(7):e147-e195. [PMC free article: PMC6590850] [PubMed: 27516382]

12.

Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020 Feb 14;69(1):1-11. [PMC free article: PMC7041302] [PubMed: 32053584]

13.

Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet. 1979 Nov-Dec;4(6):401-22. [PubMed: 391461]

14.

Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in Pregnancy. Obstet Gynecol. 2020 Jun;135(6):1444-1453. [PMC free article: PMC7975823] [PubMed: 32459437]

15.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Aug 15, 2024. Isoniazid. [PubMed: 30000395]

16.

Caraux-Paz P, Diamantis S, de Wazières B, Gallien S. Tuberculosis in the Elderly. J Clin Med. 2021 Dec 15;10(24) [PMC free article: PMC8703289] [PubMed: 34945187]

17.

Stettner M, Steinberger D, Hartmann CJ, Pabst T, Konta L, Hartung HP, Kieseier BC. Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping? Brain Behav. 2015 Aug;5(8):e00326. [PMC free article: PMC4559012] [PubMed: 26355945]

18.

Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother. 2001 Feb;45(2):382-92. [PMC free article: PMC90302] [PubMed: 11158730]

19.

Shah R, Ankale P, Sinha K, Iyer A, Jayalakshmi TK. Isoniazid Induced Lupus Presenting as Oral Mucosal Ulcers with Pancytopenia. J Clin Diagn Res. 2016 Oct;10(10):OD03-OD05. [PMC free article: PMC5121716] [PubMed: 27891378]

20.

Lee AYS. Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus. Immunol Med. 2022 Dec;45(4):180-185. [PubMed: 35383534]

21.

Constantinescu SM, Buysschaert B, Haufroid V, Broly F, Jadoul M, Morelle J. Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy - case report and literature review. BMC Nephrol. 2017 Sep 04;18(1):282. [PMC free article: PMC5584033] [PubMed: 28870161]

22.

Adithan C, Subathra A. NAT2 gene polymorphism: covert drug interaction causing phenytoin toxicity. Indian J Med Res. 2016 May;143(5):542-4. [PMC free article: PMC4989826] [PubMed: 27487996]

23.

Suzuki A, Yuen NA, Ilic K, Miller RT, Reese MJ, Brown HR, Ambroso JI, Falls JG, Hunt CM. Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™. Regul Toxicol Pharmacol. 2015 Aug;72(3):481-90. [PMC free article: PMC4548888] [PubMed: 25988394]

24.

Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf. 2002;25(2):111-33. [PubMed: 11888353]

25.

Durek C, Rüsch-Gerdes S, Jocham D, Böhle A. Sensitivity of BCG to modern antibiotics. Eur Urol. 2000;37 Suppl 1:21-5. [PubMed: 10575268]

26.

Iwamoto S, Suzuki T, Sutani A, Kuraki T, Isobe T. [A case of atypical drug-induced hypersensitivity syndrome caused by isoniazid]. Kekkaku. 2012 Dec;87(12):777-82. [PubMed: 23350519]

27.

Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf. 2014;6:145-9. [PMC free article: PMC4211866] [PubMed: 25364275]

28.

Soobratty MR, Whitfield R, Subramaniam K, Grove G, Carver A, O'Donovan GV, Wu HH, Lee OY, Swaminathan R, Cope GF, Milburn HJ. Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis. Eur Respir J. 2014 May;43(5):1519-22. [PubMed: 24435008]

29.

Subbaraman R, Thomas BE, Kumar JV, Lubeck-Schricker M, Khandewale A, Thies W, Eliasziw M, Mayer KH, Haberer JE. Measuring Tuberculosis Medication Adherence: A Comparison of Multiple Approaches in Relation to Urine Isoniazid Metabolite Testing Within a Cohort Study in India. Open Forum Infect Dis. 2021 Nov;8(11):ofab532. [PMC free article: PMC9088502] [PubMed: 35559123]

30.

Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol. 2016 Jun;81(6):1030-6. [PMC free article: PMC4876174] [PubMed: 26773235]

31.

Lee CM, Lee SS, Lee JM, Cho HC, Kim WS, Kim HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Early monitoring for detection of antituberculous drug-induced hepatotoxicity. Korean J Intern Med. 2016 Jan;31(1):65-72. [PMC free article: PMC4712436] [PubMed: 26767859]

32.

Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR., ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52. [PubMed: 17021358]

33.

Glatstein M, Carbell G, Scolnik D, Rimon A, Banerji S, Hoyte C. Pyridoxine for the treatment of isoniazid-induced seizures in intentional ingestions: The experience of a national poison center. Am J Emerg Med. 2018 Oct;36(10):1775-1778. [PubMed: 29397257]

34.

Stagg HR, Lipman MC, McHugh TD, Jenkins HE. Isoniazid-resistant tuberculosis: a cause for concern? Int J Tuberc Lung Dis. 2017 Feb 01;21(2):129-139. [PMC free article: PMC5479083] [PubMed: 28234075]

35.

Sotgiu G, Centis R, D'ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med. 2015 Jan 08;5(5):a017822. [PMC free article: PMC4448591] [PubMed: 25573773]

Disclosure: Courtney O'Connor declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Mark Brady declares no relevant financial relationships with ineligible companies.